Posted in

Global Divide: Why Early Cancer Diagnosis Fails Women in LMICs

•Posted inMedical Updates
Doctor reviewing dermatology cases using diagnostic tools during clinical rounds.

A recent Lancet study highlights significant global disparities in early cancer diagnosis for women. Less than one-fifth (under 20 percent) of women with breast or cervical cancer in low and middle-income countries (LMICs) receive an early diagnosis. However, two in every five women (40 percent) in high-income countries (HICs) are diagnosed early. This crucial difference profoundly impacts patient survival rates. Advanced-stage cancers significantly reduce treatment efficacy, making early detection a worldwide priority to enhance health outcomes for women.

Understanding Disparities in Early Cancer Diagnosis

The ‘VENUSCANCER’ study, led by the London School of Hygiene and Tropical Medicine’s ‘Cancer Survival Group,’ provides an extensive global database. It covers three common women’s cancers: breast, cervical, and ovarian. This detailed analysis reviewed diagnosis trends and adherence to international guidelines for over 275,000 women across 39 countries from 2015 to 2018. Findings reveal a troubling divide; women in LMICs often receive diagnoses only when cancer is advanced. This late detection significantly reduces their survival chances compared to women in wealthier nations.

Ovarian cancer consistently shows the lowest rates of early diagnosis worldwide, remaining under 20 percent across all regions. It is frequently called a ‘silent killer’ because vague symptoms, such as abdominal pain and swelling, often go unnoticed for extended periods. Consequently, many women receive a late-stage diagnosis. Furthermore, the study noted that surgery is generally offered for early-stage cancer in most countries. However, this treatment may not always align with international guidelines.

Challenges in Early Cancer Diagnosis and Treatment

The study also revealed significant differences in metastatic breast cancer prevalence. In most HICs, metastatic breast cancers, where the disease has spread, account for under 10 percent of cases. Conversely, in LMICs, this figure dramatically ranges from two to 44 percent. This wide range indicates varying health system capacities and diagnostic infrastructure. Moreover, older women frequently receive less guideline-aligned treatment than younger women, showing another disparity in care.

Access barriers and health system limitations greatly contribute to diagnostic and care delays in LMICs. For instance, financial challenges, geographic obstacles, and low health literacy are common hurdles. Patients in LMICs often experience considerable delays. An average of 7.4 months passes from symptom onset to diagnosis, and 4.9 months from diagnosis to treatment. These prolonged intervals directly affect successful treatment and survival probabilities.

Policy Implications and Global Initiatives

Population-based cancer registries are pivotal for monitoring treatment consistency with clinical guidelines. They also assess the impact on patient survival. Lead author Claudia Allemani, Professor of Global Public Health at LSHTM, stresses that governments must provide stable financial support for these registries. This support should be part of national cancer control plans. Study evidence offers crucial insights for global cancer control policies, including WHO’s Global Breast Cancer Initiative and the Cervical Cancer Elimination Initiative. To gain a deeper understanding of managing and treating various cancers, consider exploring our Oncology Speciality Courses.

The WHO’s Cervical Cancer Elimination Initiative, launched in 2020, sets ambitious 90-70-90 targets for 2030. These include vaccinating 90% of girls with HPV by age 15. Also, 70% of women need screening with a high-performance test by ages 35 and 45. Finally, 90% of women with pre-cancer must be treated, and 90% with invasive cancer managed. Meeting these targets is vital for eliminating cervical cancer as a public health problem. Similarly, the Global Breast Cancer Initiative aims to cut breast cancer mortality by 2.5% annually. It achieves this by strengthening health systems, improving early diagnosis, and ensuring timely, quality care. Both initiatives highlight the importance of early detection and equitable access to care.

Frequently Asked Questions

Q1: Why is early cancer diagnosis less common in low and middle-income countries?

Early cancer diagnosis is less common due to several factors. These include limited health system capacities, financial challenges, and geographic barriers to healthcare access. Lower health literacy among populations also contributes. Furthermore, vague symptoms for cancers like ovarian cancer often lead to delayed presentation and diagnosis.

Q2: What is the ‘VENUSCANCER’ study?

The ‘VENUSCANCER’ study is a comprehensive international research effort. It was led by the London School of Hygiene and Tropical Medicine. This study analyzed trends in care, including diagnosis and adherence to international guidelines. It covered over 275,000 women across 39 countries diagnosed with breast, cervical, and ovarian cancers between 2015 and 2018. It represents the largest global population-based database for these cancers to date.

Q3: How do population-based cancer registries help improve cancer care?

Population-based cancer registries are crucial tools. They assess and monitor the consistency of cancer treatment with clinical guidelines. They also evaluate the impact of these guidelines on patient survival. These registries provide essential data. This data informs public health policies, identifies disparities, and guides resource allocation for cancer control plans.

References

  1. Study shows less than 20 pc of women in low and middle-income countriesdiagnosed with cancer at early stage – ETHealthworld
  2. Groundbreaking Global Study Reveals Vast Disparities in Women’s Cancer Care. Vertex AI Search.
  3. Cancer screening and early diagnosis in low and middle income countries: Current situation and future perspectives | Request PDF – ResearchGate.
  4. Early Detection of Breast and Cervical Cancer in LMICs Remains at 20 Percent Compared to Over 33 Percent in HICs – GeneOnline.
  5. Cancer Care Inequity for Women in Resource-Poor Countries – PMC – PubMed Central.
  6. A Scoping Review on Barriers to Cancer Diagnosis and Care in Low- and Middle-Income Countries – AACR Journals.
  7. Challenges to the early diagnosis and treatment of breast cancer in developing countries – PMC – PubMed Central.
  8. Global cancer burden growing, amidst mounting need for services.
  9. Bridging the Gap: Addressing Global Disparities in Women’s Cancer Diagnoses | Health.
  10. Delays and Barriers to Cancer Care in Low‐ and Middle‐Income Countries: A Systematic Review – PubMed Central.
  11. Cervical Cancer Elimination Initiative – World Health Organization (WHO).
  12. Cervical cancer | UICC.
  13. Cervical Cancer Elimination – CCAE.
  14. WHO CERVICAL CANCER ELIMINATION INITIATIVE – World Health Organization (WHO).
  15. Worldwide initiatives to eliminate cervical cancer – PMC.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.